CASE REPORT
Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor α neutralizing antibody
Full Text (PDF)
Shunsuke Mori1, Fumiya Imamura2, Chikage Kiyofuji2, Kanako Ito3, Yukinori Koga3, Izumi Honda2 and Mineharu Sugimoto2
| (1) |
Division of Rheumatology, Department of Medicine, National Hospital Organization, Kumamoto Saishunso National Hospital, Suya 2659 Nishigohshi-machi, Kikuchi-gun, Kumamoto 860-1196, Japan |
| (2) |
Division of Respiratory Medicine, Department of Medicine, National Hospital Organization, Kumamoto Saishunso National Hospital, Kumamoto, Japan |
| (3) |
Department of Radiology, National Hospital Organization, Kumamoto Saishunso National Hospital, Kumamoto, Japan |
Received: 19 October 2005 Accepted: 21 December 2005
Abstract We report that a-63-year-old woman developed Pneumocystis jiroveci pneumonia (PCP) as a complication from treatment with infliximab for rheumatoid arthritis. Although there was neither symptoms of dyspnea nor typical observations on a chest X-ray examination, low levels of oxygen saturation and findings of high-resolution chest computed tomographic scanning suggested a possibility of interstitial pneumonia. A polymerase chain reaction-based detection of Pneumocystis jiroveci in induced sputum allowed an early diagnosis of PCP and subsequent effective treatment.
Key words Infliximab - Pneumocystis jiroveci - Polymerase chain reaction - Rheumatoid arthritis (RA) - Tumor necrosis factor
The references of this article are secured to subscribers.
|
